Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast Cancer
Clinical trial NCT06483386 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06483386
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-07-15
- Primary completion
- 2026-06-30
- Enrollment
- 109
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.